Mer­ck, Kelun trum­pet Phase 3 breast can­cer da­ta for an­ti-TROP2 ADC

Mer­ck and Kelun-Biotech re­vealed Phase 3 breast can­cer da­ta for the lead an­ti­body-drug con­ju­gate in their po­ten­tial­ly $12 bil­lion part­ner­ship.

In a Phase 3 tri­al …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER